Vincristine Sulfate
Product Description
Vincristine Sulfate
Application Notes
Vincristine Sulfate is used to treat acute leukaemia, malignant lymphoma, Hodgkin′s disease, acute erythraemia, acute panmyelosis, breast cancer, Kaposi’s sarcoma and testicular cancer. It is widely used in cancer research. It is used to study multi-drug resistance. It is used to inhibit cell cycle progression at M-phase and to inhibit monoamine oxidase (MAO).
Usage Statement
Research Use Only (RUO). Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Key Applications
Antitumor agent||Treatment of acute leukaemia; malignant lymphoma; Hodgkin′s disease; acute erythraemia; acute panmyelosis; Breast cancer
| SKU | 02190687-CF |
| Alternate Names | 22-oxo-vincaleukoblastine sulfate; Leuocristine sulfate (1:1); Vincrisul; VCR |
| Application Notes | Vincristine Sulfate is used to treat acute leukaemia, malignant lymphoma, Hodgkin′s disease, acute erythraemia, acute panmyelosis, breast cancer, Kaposi’s sarcoma and testicular cancer. It is widely used in cancer research. It is used to study multi-drug resistance. It is used to inhibit cell cycle progression at M-phase and to inhibit monoamine oxidase (MAO). |
| Beilstein Registry Number | 3924631 |
| Biochemical Physiological Actions | Vincristine is a plant alkaloid that inhibits microtubule assembly by binding tubulin and inducing coiled spiral aggregate formation. It arrests cell cycle in G2/M-phase by blocking mitotic spindle formation. Vincristine triggers Raf-1 activation, phosphorylation of bcl-2-family proteins, induction of p53 expression, and apoptosis in several tumor cell lines. It inhibits VEGF production in leukemia cell lines. It is a substrate for Pgp and CYP3A4. MRP1 transports vincristine in an ATP- and GSH-dependent manner. Vincristine has some immunosuppressant effect. Vincristine may also interfere with amino acid, cyclic AMP, and glutathione metabolism, calmodulin-dependent Ca2+-transport, cellular respiration, and nucleic acid and lipid biosynthesis. |
| EC Number | 218-190-0 |
| Format | powder |
| Hazard Statements | H300-H341-H361fd |
| Applications | Antitumor agent||Treatment of acute leukaemia; malignant lymphoma; Hodgkin′s disease; acute erythraemia; acute panmyelosis; Breast cancer |
| MDL # | MFCD00084729 |
| Melting Point | 531° F approximately (NTP, 1992) |
| Molecular Formula | C46H58N4O14S |
| Molecular Weight | 923.044 g/mol |
| Physical Appearance | White Powder |
| Product Families Description | Vincristine sulfate |
| Product Overview | Vincristine Sulfate |
| RTECS Number | OH6340000 |
| Safety Symbol | GHS06, GHS08 |
| Solubility | greater than or equal to 10 mg/mL at 75° F (NTP, 1992) |
| Storage and Handling | Store at +4 °C; desiccate; protect from light. |
| Usage Statement | Research Use Only (RUO). Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. |